


CLAIMS

1. A compound represented by formula (I)



[Chemical formula 1]



[wherein

Q refers to a group represented by the following formula (A) or (B):

[Chemical formula 2]



R¹ is hydroxyl, C₁-C₆ alkoxy, or NR^{1A}R^{1B};

R^{1A} and R^{1B}, which may be the same or different, are each a hydrogen atom, C₁-C₆ alkyl or C₃-C₇ cycloalkyl, or

R^{1A} and R^{1B} are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C₁-C₆ alkyls);

R² is a hydrogen atom, a halogen atom, or C₁-C₆ alkyl;

n is 1 or 2;

R³ is a hydrogen atom, a halogen atom, or C₁-C₆ alkyl;


R⁴ is C₁-C₆ alkyl (the C₁-C₆ alkyl may be substituted by one or two C₃-C₇ cycloalkyls) or C₃-C₇ cycloalkyl (the C₃-C₇ cycloalkyl may be substituted by one or two C₁-C₆ alkyls);

R⁵ and R⁶, which may be the same or different, are each C₁-C₆ alkyl or C₃-C₇ cycloalkyl, or

R⁵ and R⁶ are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C₁-C₆ alkyls)] or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein Q is represented by formula (A):

[Chemical formula 3]



(wherein R⁴ is as defined in claim 1), or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or 2, wherein R¹ is NR^{1A}R^{1B} (wherein R^{1A} and R^{1B} are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3, wherein R² and R³ are each a hydrogen atom and n is 1, or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of claims 1 to 4, wherein R⁴ is C₃-C₇ cycloalkyl, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical agent comprising as the active ingredient a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.


7. A pharmaceutical agent according to claim 6 which is a histamine H₃ receptor antagonist or inverse agonist.

8. A pharmaceutical agent according to claim 6 or 7 which is a preventive or therapeutic agent for dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis.

CLAIMS

1. A compound represented by formula (I)


[Chemical formula 1]



[wherein

Q refers to a group represented by the following formula (A) or (B):

[Chemical formula 2]



R^1 is hydroxyl, C_1 - C_6 alkoxy, or $NR^{1A}R^{1B}$;

R^{1A} and R^{1B} , which may be the same or different, are each a hydrogen atom, C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl, or

R^{1A} and R^{1B} are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C_1 - C_6 alkyls);

R^2 is a hydrogen atom, a halogen atom, or C_1 - C_6 alkyl;

n is 1 or 2;

R^3 is a hydrogen atom, a halogen atom, or C_1 - C_6 alkyl;


R^4 is C_1 - C_6 alkyl (the C_1 - C_6 alkyl may be substituted by one or two C_3 - C_7 cycloalkyls) or C_3 - C_7 cycloalkyl (the C_3 - C_7 cycloalkyl may be substituted by one or two C_1 - C_6 alkyls);

R⁵ and R⁶, which may be the same or different, are each C₁-C₆ alkyl or C₃-C₇ cycloalkyl, or

R⁵ and R⁶ are bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C₁-C₆ alkyls)] or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein Q is represented by formula (A):

[Chemical formula 3]



(wherein R⁴ is as defined in claim 1), or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or 2, wherein R¹ is NR^{1A}R^{1B} (wherein R^{1A} and R^{1B} are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3, wherein R² and R³ are each a hydrogen atom and n is 1, or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of claims 1 to 4, wherein R⁴ is C₃-C₇ cycloalkyl, or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 which is selected from the group consisting of the following or a pharmaceutically acceptable salt thereof:

Methyl 1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrole-3-carboxylate,

1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrole-3-carboxylic acid,

Azetidin-1-yl(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)

methanone,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(pyrrolidin-1-yl)

methanol,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(piperidin-1-yl)

methanol,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-N,N-dimethyl-1H-pyrrole-3-carboxamide,

1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-N-methyl-1H-pyrrole-3-carboxamide,

1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrole-3-carboxamide,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(morpholin-4-yl)

methanone,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)((2R,6S)-2,6-dimethylmorpholin-4-yl)methanone,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(2-oxa-6-azaspiro[3.3]hepta-6-yl)methanone,

N-tert-butyl-1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrole-3-carboxamide,

N-cyclobutyl-1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-1H-pyrrole-3-carboxamide,

Methyl 1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-2,5-dimethyl-1H-pyrrole-3-carboxylate,

(1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-2,5-dimethyl-1H-pyrrol-3-yl)

(pyrrolidin-1-yl)methanone,

[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrrol-3-yl](pyrrolidin-1-yl)methanone ,

(1-{4-[(1-isopropylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(pyrrolidin-1-yl)

methanone,


1-{4-[(1-isopropylpiperidin-4-yl)oxy]phenyl}-N-methyl-1H-pyrrole-3-carboxamide,

(1-{4-[(1-tert-butylpiperidin-4-yl)oxy]phenyl}-1H-pyrrol-3-yl)(pyrrolidin-1-yl)

methanone, and

1-{4-[(1-tert-butylpiperidin-4-yl)oxy]phenyl}-N-methyl-1H-pyrrole-3-carboxamide.

7. A compound according to claim 1 which is
1-{4-[(1-cyclobutylpiperidin-4-yl)oxy]phenyl}-N-methyl-1H-pyrrole-3-
carboxamide represented by the following formula or a pharmaceutically acceptable salt
thereof



8. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof for use as a pharmaceutical agent.
9. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof for use as a histamine H3 receptor antagonist or inverse agonist.
10. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof for use as a preventive or therapeutic agent for dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis.